EgyptTuberculosis profile
Population  2016 96 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.29 (0.27–0.3) 0.3 (0.28–0.31)
Mortality (HIV+TB only) 0.011 (<0.01–0.017) 0.01 (0.01–0.02)
Incidence  (includes HIV+TB) 13 (12–15) 14 (12–15)
Incidence (HIV+TB only) 0.031 (0.02–0.044) 0.03 (0.02–0.05)
Incidence (MDR/RR-TB)** 2.1 (1.8–2.5) 2.2 (1.9–2.6)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.62 (0.56–0.69) 4.9 (4.3–5.4) 5.5 (4.9–6.1)
Males 0.7 (0.63–0.78) 7 (6.2–7.7) 7.7 (6.8–8.5)
Total 1.3 (1.2–1.5) 12 (11–13) 13 (12–15)
TB case notifications, 2016  
Total cases notified 8 283
Total new and relapse 7 974
          - % tested with rapid diagnostics at time of diagnosis 22%
          - % with known HIV status 24%
          - % pulmonary 57%
          - % bacteriologically confirmed among pulmonary 82%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 61% (55–68)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.02 (0.02–0.03)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 16 <1%
          - on antiretroviral therapy 16 100%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  720
(620–830)
Estimated % of TB cases with MDR/RR-TB 14% (12–16) 20% (17–24)  
% notified tested for rifampicin resistance 29% 94% 2 799
MDR/RR-TB cases tested for resistance to second-line drugs   11
Laboratory-confirmed cases MDR/RR-TB: 174, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 86, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 85% 7 860
Previously treated cases, excluding relapse, registered in 2015 64% 295
HIV-positive TB cases registered in 2015 79% 14
MDR/RR-TB cases started on second-line treatment in 2014 63% 76
XDR-TB cases started on second-line treatment in 2014 100% 1
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
25% (23–28)
TB financing, 2017  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-12-17 Data: www.who.int/tb/data